User menu

A phase II, placebo-controlled study of merimepodib (VX-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin

Bibliographic reference Marcellin, P. ; Horsmans, Yves ; Nevens, Frederik ; Grange, JD ; Bronowicki, JP ; et. al. A phase II, placebo-controlled study of merimepodib (VX-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin.39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (Berlin (Germany), Apr 14-18, 2004). In: Journal of Hepatology, Vol. 40, p. 145-145 (2004)
Permanent URL http://hdl.handle.net/2078.1/61296